Literature DB >> 26923605

ACE and ARB Agents in the Prophylactic Therapy of Migraine-How Effective Are They?

Rashmi B Halker1, Amaal J Starling1, Bert B Vargas1, Todd J Schwedt2.   

Abstract

OPINION STATEMENT: Angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) are antihypertensive agents that can be considered for migraine preventative therapy. Although the exact mechanisms by which ACE inhibitors and ARBs may work for migraine prophylaxis are unknown, there are several plausible hypotheses as to why modulating the activity of the renin angiotensin system could result in migraine prevention. Clinical trials of ACE inhibitors and ARBs provide evidence that they are effective and generally well tolerated when used for migraine prophylaxis. Based upon biologic plausibility, the quality of evidence for efficacy from clinical trials, and recommendations in published guidelines, we consider ACE inhibitors and ARBs as second- or third-line options for migraine prophylaxis.

Entities:  

Keywords:  Angiotensin converting enzyme inhibitors; Angiotensin receptor blockers; Headache; Migraine

Year:  2016        PMID: 26923605     DOI: 10.1007/s11940-016-0397-2

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  24 in total

Review 1.  Episodic and chronic migraine headache: breaking down barriers to optimal treatment and prevention.

Authors:  Richard B Lipton; Stephen D Silberstein
Journal:  Headache       Date:  2015-03       Impact factor: 5.887

Review 2.  Involvement of the renin-angiotensin system in migraine.

Authors:  Erling Tronvik; Lars J Stovner; Harald Schrader; Gunnar Bovim
Journal:  J Hypertens Suppl       Date:  2006-03

3.  Migraine prevalence, disease burden, and the need for preventive therapy.

Authors:  R B Lipton; M E Bigal; M Diamond; F Freitag; M L Reed; W F Stewart
Journal:  Neurology       Date:  2007-01-30       Impact factor: 9.910

Review 4.  Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society.

Authors:  S D Silberstein; S Holland; F Freitag; D W Dodick; C Argoff; E Ashman
Journal:  Neurology       Date:  2012-04-24       Impact factor: 9.910

5.  Association of the insertion/deletion polymorphism of the angiotensin I-converting enzyme gene in patients of migraine with aura.

Authors:  Hisanori Kowa; Emi Fusayasu; Tamami Ijiri; Kumiko Ishizaki; Kenichi Yasui; Kazuhiro Nakaso; Masayoshi Kusumi; Takao Takeshima; Kenji Nakashima
Journal:  Neurosci Lett       Date:  2005-02-10       Impact factor: 3.046

6.  [Captopril versus placebo in the prevention of hemicrania without aura. A randomized double-blind study].

Authors:  S Paterna; P di Pasquale; S Martino; A Arrostuto; N C Ingurgio; G Parrinello; D Gullotti; G Licata
Journal:  Clin Ter       Date:  1992-12

7.  Microinjection of angiotensin II in the caudal ventrolateral medulla induces hyperalgesia.

Authors:  J Marques-Lopes; M Pinto; D Pinho; M Morato; D Patinha; A Albino-Teixeira; I Tavares
Journal:  Neuroscience       Date:  2008-12-07       Impact factor: 3.590

8.  Association between ACE inhibitors use and headache caused by nitrates among hypertensive patients: results from the Italian group of pharmacoepidemiology in the elderly (GIFA).

Authors:  G Onder; M Pahor; G Gambassi; A Federici; A Savo; P Carbonin; R Bernabei
Journal:  Cephalalgia       Date:  2003-11       Impact factor: 6.292

9.  Telmisartan in migraine prophylaxis: a randomized, placebo-controlled trial.

Authors:  H C Diener; A Gendolla; A Feuersenger; S Evers; A Straube; H Schumacher; G Davidai
Journal:  Cephalalgia       Date:  2009-09       Impact factor: 6.292

10.  A Comparative Effectiveness Meta-Analysis of Drugs for the Prophylaxis of Migraine Headache.

Authors:  Jeffrey L Jackson; Elizabeth Cogbill; Rafael Santana-Davila; Christina Eldredge; William Collier; Andrew Gradall; Neha Sehgal; Jessica Kuester
Journal:  PLoS One       Date:  2015-07-14       Impact factor: 3.240

View more
  7 in total

1.  Efficacy of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in the Preventative Treatment of Episodic Migraine in Adults.

Authors:  T Dorosch; C A Ganzer; M Lin; A Seifan
Journal:  Curr Pain Headache Rep       Date:  2019-09-12

2.  An evidence-based systematic review of the off-label uses of lisinopril.

Authors:  Seyyed-Reza Sadat-Ebrahimi; Neda Parnianfard; Nafiseh Vahed; Hossein Babaei; Morteza Ghojazadeh; Sydney Tang; Amir Azarpazhooh
Journal:  Br J Clin Pharmacol       Date:  2018-09-11       Impact factor: 4.335

3.  Treatment with telmisartan, a long-acting angiotensin II receptor blocker, prevents migraine attacks in Japanese non-responders to lomerizine.

Authors:  Ken Ikeda; Sayori Hanashiro; Yuichi Ishikawa; Masahiro Sawada; Maya Kyuzen; Harumi Morioka; Junya Ebina; Junpei Nagasawa; Masaru Yanagihashi; Ken Miura; Takehisa Hirayama; Takanori Takazawa; Osamu Kano; Kiyokazu Kawabe; Yasuo Iwasaki
Journal:  Neurol Sci       Date:  2017-02-21       Impact factor: 3.307

Review 4.  Structural and functional connections between the autonomic nervous system, hypothalamic-pituitary-adrenal axis, and the immune system: a context and time dependent stress response network.

Authors:  Bridget Mueller; Alex Figueroa; Jessica Robinson-Papp
Journal:  Neurol Sci       Date:  2022-01-16       Impact factor: 3.307

Review 5.  Pharmacogenetics in Primary Headache Disorders.

Authors:  Irina I Belyaeva; Anna G Subbotina; Ivan I Eremenko; Vadim V Tarasov; Vladimir N Chubarev; Helgi B Schiöth; Jessica Mwinyi
Journal:  Front Pharmacol       Date:  2022-02-10       Impact factor: 5.810

6.  The relationship of headache as a symptom to COVID-19 survival: A systematic review and meta-analysis of survival of 43,169 inpatients with COVID-19.

Authors:  Víctor J Gallardo; Robert E Shapiro; Edoardo Caronna; Patricia Pozo-Rosich
Journal:  Headache       Date:  2022-09-02       Impact factor: 5.311

7.  Migraine Care in the Era of COVID-19: Clinical Pearls and Plea to Insurers.

Authors:  Christina L Szperka; Jessica Ailani; Rebecca Barmherzig; Brad C Klein; Mia T Minen; Rashmi B Halker Singh; Robert E Shapiro
Journal:  Headache       Date:  2020-04-03       Impact factor: 5.311

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.